Anti-BCMA CAR T Cells BB2121
Biologic therapy (BRM, immunotherapy)
March 26, 2021: FDA approved idecabtagene vicleucel (Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
This drug should be coded